

# CITATION REPORT

List of articles citing

The effect of hypoglycemia on health-related quality of life: Canadian results from a multinational time trade-off survey

DOI: 10.1016/j.jcjd.2013.09.001

Canadian Journal of Diabetes, 2014, 38, 45-52.

**Source:** <https://exaly.com/paper-pdf/58900014/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
56	The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 827-36	2.4	5
55	Association between post-dinner dietary intakes and nocturnal hypoglycemic risk in adult patients with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2014</b> , 106, 420-7	7.4	11
54	Factors associated with nocturnal hypoglycemia in at-risk adolescents and young adults with type 1 diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2015</b> , 17, 385-91	8.1	34
53	Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes. <i>Diabetology and Metabolic Syndrome</i> , <b>2015</b> , 7, 35	5.6	2
52	Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice. <i>Journal of Comparative Effectiveness Research</i> , <b>2015</b> , 4, 279-286	2.1	1
51	Evaluating health-related quality of life in type 1 diabetes: a systematic literature review of utilities for adults with type 1 diabetes. <i>ClinicoEconomics and Outcomes Research</i> , <b>2016</b> , 8, 559-571	1.7	24
50	Making Insulin Accessible: Does Inhaled Insulin Fill an Unmet Need?. <i>Advances in Therapy</i> , <b>2016</b> , 33, 1267-78	7.8	12
49	History of mild hypoglycaemia does not affect the prevalence of diabetes-related distress in people with diabetes. <i>Acta Diabetologica</i> , <b>2016</b> , 53, 833-8	3.9	5
48	Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1719-1725	7.5	4
47	Use of liraglutide in type 1 diabetes: implications for management. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 190-191	18.1	
46	Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. <i>Diabetes Technology and Therapeutics</i> , <b>2016</b> , 18, 75-84	8.1	28
45	Quantifying Worry in the Face of Uncertainty: Radiation Exposure from Medical Imaging. <i>Journal of Medical Imaging and Radiation Sciences</i> , <b>2017</b> , 48, 16-21	1.4	2
44	Health-related quality of life and utility values associated to hypoglycemia in patients with type 1 diabetes mellitus treated in the Brazilian Public Health System: a multicenter study. <i>Diabetology and Metabolic Syndrome</i> , <b>2017</b> , 9, 9	5.6	7
43	The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1045-1055	2.5	7
42	Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes. <i>Diabetes Therapy</i> , <b>2017</b> , 8, 213-217	3.6	1
41	Self-reported Hypoglycaemia in Patients treated with Insulin: A Large Slovenian Retrospectively-prospective Study. <i>Zdravstveno Varstvo</i> , <b>2017</b> , 56, 244-250	1.3	1
40	Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing Challenges. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, S1-S11	3.5	6

39	Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications. <i>Clinical Diabetes</i> , <b>2018</b> , 36, 149-159	2.9	10
38	Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 1227-1234	14.6	37
37	Severity of hypoglycaemia and health-related quality of life, work productivity and healthcare costs in patients with type 2 diabetes in Europe. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2018</b> , 1, e00011	2.7	7
36	The Canadian Hypoglycemia Assessment Tool Program: Insights Into Rates and Implications of Hypoglycemia From an Observational Study. <i>Canadian Journal of Diabetes</i> , <b>2018</b> , 42, 11-17	2.1	18
35	Management of hyperglycemia during and in the immediate follow-up of acute coronary syndrome. <i>Journal of the Saudi Heart Association</i> , <b>2018</b> , 30, 113-121	0.7	2
34	Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. <i>Medical Decision Making</i> , <b>2018</b> , 38, 942-953	2.5	9
33	Estimating the utility value of hypoglycaemia according to severity and frequency using the visual analogue scale (VAS) and time trade-off (TTO) survey. <i>Journal of Diabetes and Metabolic Disorders</i> , <b>2018</b> , 17, 269-275	2.5	3
32	Cost-effectiveness and budget impact of liraglutide in type 2 diabetes patients with elevated cardiovascular risk: a US-managed care perspective. <i>ClinicoEconomics and Outcomes Research</i> , <b>2018</b> , 10, 791-803	1.7	9
31	Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 170-178	8	19
30	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial. <i>Diabetes Care</i> , <b>2018</b> , 41, 1938-1946	14.6	141
29	Does hypoglycaemia affect the improvement in QoL after the transition to insulin in people with type 2 diabetes?. <i>Journal of Endocrinological Investigation</i> , <b>2018</b> , 41, 249-258	5.2	6
28	Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonyleurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective. <i>International Journal of Endocrinology</i> , <b>2018</b> , 2018, 3718958	2.7	1
27	Insomnia and Mild Cognitive Impairment. <i>Gerontology and Geriatric Medicine</i> , <b>2018</b> , 4, 2333721418778421.3	2.3	5
26	Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal-Bolus Therapy. <i>Diabetes Therapy</i> , <b>2019</b> , 10, 1347-1356	3.6	3
25	Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1706-1714	6.7	3
24	The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan. <i>Value in Health Regional Issues</i> , <b>2019</b> , 18, 84-90	1.6	2
23	Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. <i>Diabetology and Metabolic Syndrome</i> , <b>2019</b> , 11, 2	5.6	19
22	A cost-utility analysis of dulaglutide versus insulin glargine as third-line therapy for Type 2 diabetes in Canada. <i>Journal of Comparative Effectiveness Research</i> , <b>2019</b> , 8, 229-240	2.1	3

21	The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities. <i>Pharmacoeconomics - Open</i> , <b>2019</b> , 3, 197-204	2.1	
20	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2020</b> , 22, 812-821	8.1	9
19	Adjunct therapies in treatment of type 1 diabetes. <i>Journal of Diabetes</i> , <b>2020</b> , 12, 742-753	3.8	8
18	Conversations and Reactions Around Severe Hypoglycemia Study: Results of Hypoglycemia Experiences in Canadian Adults With Insulin-Treated Diabetes and Their Caregivers. <i>Canadian Journal of Diabetes</i> , <b>2021</b> , 45, 236-242	2.1	6
17	The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data. <i>Journal of Patient-Reported Outcomes</i> , <b>2021</b> , 5, 6	2.6	3
16	Long-term (52-week) efficacy and safety of dapagliflozin as an adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1496-1504	6.7	3
15	Pharmacogenetic-guided glimepiride therapy in type-2 diabetes mellitus: a cost-effectiveness study. <i>Pharmacogenomics Journal</i> , <b>2021</b> , 21, 559-565	3.5	1
14	Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes. <i>Journal of Comparative Effectiveness Research</i> , <b>2021</b> , 10, 961-974	2.1	0
13	Effects of continuous glucose monitor-recorded nocturnal hypoglycaemia on quality of life and mood during daily life in type 1 diabetes. <i>Diabetologia</i> , <b>2021</b> , 64, 903-913	10.3	4
12	Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study. <i>Pharmacogenomics</i> , <b>2021</b> , 22, 1057-1068	2.6	0
11	Health-related quality of life in a group of Egyptian children and adolescents with type 1 diabetes: relationship to microvascular complications. <i>Bulletin of the National Research Centre</i> , <b>2019</b> , 43,	3	1
10	Prediction of Hypoglycemia By Quality of Life Measures: A Retrospective Analysis of Electronically Patient-Reported Data. <i>Endocrine Practice</i> , <b>2020</b> , 26, 1153-1165	3.2	
9	Evaluation of the cost and medical resource use outcomes associated with nasal glucagon versus injectable glucagon for treatment of severe hypoglycemia in people with diabetes in Canada: a modelling analysis.. <i>Journal of Medical Economics</i> , <b>2022</b> , 1-32	2.4	
8	The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study.. <i>JMIR Research Protocols</i> , <b>2022</b> , 11, e35461	2	0
7	The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study (Preprint).		
6	Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA. <i>Clinical Drug Investigation</i> ,	3.2	0
5	The Cost of Control: Cost-Effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. <i>Diabetes Care</i> ,	14.6	0
4	Nationally Subsidized Continuous Glucose Monitoring: A Cost-effectiveness Analysis.		0

- 3 First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. 4
- 2 Health State Utility Values of Type 2 Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis. **2023**, 34, 14-22 ○
- 1 Economic Burdens of Type 2 Diabetes Hospital Visits with Hypoglycemic Episodes in the Tertiary Care Setting in Thailand. **2023**, 11, 949 ○